NeurologyLive® Friday 5 — December 31, 2021

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: NeurologyLive^® Year in Review 2021: FDA Stories

FDA actions are a foundational part of the NeurologyLive^® team's coverage each year, as many of these approvals marked important moments for a number of patient populations and their health care professionals. Any addition to the therapeutic landscape of a disease is a welcome sign, as each new therapy provides a new approach to care.

2: Gait Dysfunction in Parkinson Disease: The Role of the Cholinergic System

In the cover story of the NeurlogyLive^® December issue, W. Alex Dalrymple, MD, writes that although combination carbidopa-levodopa has become a standard for the treatment of many of the motor features of Parkinson disease to this day, gait dysfunction remains a difficult symptom to treat.

3: NeuroVoices: Anne Kelly, MD, on Evaluating and Improving Care for Migraine in the ED

The director of the Joseph Epstein Center for Emergency Medicine Research discussed the treatment of migraine presenting to the emergency department, why there is a need for guidelines developed by international bodies to provide crucial direction for emergency departments in how they treat presenting headache, and more.

4: Podcast: Episode 54: The Shortage of Neurologists

Mind Moments™, a podcast from NeurologyLive^®, brings you an exclusive interview with Jennifer Majersik, MD, MS, division chief of vascular neurology, University of Utah, who discussed the ongoing shortage of neurologists and the individual role that clinicians and neurologists can play to increase interest in the field.

5: NeurologyLive^® Year in Review 2021: Top Q&As

As part of NeurologyLive^®'s Year in Review, take a look at some of the most engaging conversations the team has had with experts in neurology this past year on topics such as the shortage of physicians, progress made in NMOSD care, new clinical guidelines, landmark approvals, novel biomarkers, and more

—————————————————

Introducing: Giants of Multiple Sclerosis™

Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.

Nominate Someone Today for a 2022 Giants of Multiple Sclerosis™ Award

• Nominations are open through January 31, 2022
• The Giants of Multiple Sclerosis™ Steering Committee will vet all nominations and vote to determine the 2022 inductees
• Nominees will be selected on the merits of their lifetime work.
• One honoree in each category who makes a measurable difference in the lives of patients will be awarded.
• The 2022 Giants of Multiple Sclerosis™ inaugural class will be announced in Spring of 2022

Nominate someone here.